Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma giant.

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Richard Gonzalez is retiring as chairman of AbbVie. "AbbVie Names CEO Robert Michael Chairman as Richard Gonzales Retires," at 8:20 a.m. ET, misspelled his name as Gonzales in the headline and article ...

AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.

AbbVie and Xilio Therapeutics have announced a collaboration to develop innovative tumor-activated immunotherapies, including masked T-cell engagers, utilizing Xilio’s proprietary technology ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Jamie Kelter Davis / Bloomberg via Getty Images AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two ...